Valneva SE
| Societas Europaea | |
| Traded as | Euronext: VLA |
| Industry | Biotechnology |
| Fate | established through a merger of former Intercell and Vivalis SA |
| Founded | 2013 |
| Headquarters | Lyon, France |
Key people | Thomas Lingelbach (CEO), Frédéric Grimaud (Chairman of the supervisory board) |
| Products | Development of vaccines |
| Website |
www |
Valneva SE is a biotechnology company based in France and Austria which focuses on the development of modern prophylactic vaccines against infectious diseases. Valneva was founded in 2013 by a merger of Intercell and Vivalis SA.[1]
It employs approximately 400 people in Austria, Canada, England, France, Scotland, Sweden and the United States.[2] It has been listed on the Euronext since May 28, 2013.
Valneva cooperates with pharmaceutical companies like Novartis, Merck, Sanofi-Aventis and GlaxoSmithKline on vaccine production.
The most important products of Valneva are:
- IXIARO, vaccine against Japanese encephalitis (approved in Europe, America and Australia)[3]
Valneva vaccine candidates are (as of 2017):
- VLA84, vaccine candidate against Clostridium difficile[5]
- VLA15, vaccine candidate against Lyme borreliosis[6]
Other Valneva projects are:
- Antigen identification program and adjuvant technologies
- Vaccine Enhancement Patch to improve prevention against pandemic influenza (in collaboration with U.S. Department of Health and Human Services)
Considerable failed vaccine candidates were:
- VLA43, therapeutic vaccine against Pseudomonas Aeruginosa[7]
- V710, therapeutic vaccine against Staphylococcus aureus (in collaboration with Merck)[8]
- IC41, therapeutic vaccine against hepatitis C[9]
References
- ↑ "Abschluss der Verschmelzung von Vivalis und Intercell zur Bildung von Valneva". Retrieved 2017-04-25.
- ↑ "Frankreich: Die EIB vergibt einen Kredit über € 25 Mio. für Forschung & Entwicklung an Valneva". European Investment Bank. Retrieved 2017-04-25.
- ↑ "Ixiaro, Japanese-encephalitis vaccine (inactivated, adsorbed)". European Medicines Agency (EMA). 2009-06-05. Retrieved 2017-04-25.
- ↑ "Dukoral, cholera vaccine (inactivated, oral)". European Medicines Agency (EMA). 2009-04-30. Retrieved 2017-04-25.
- ↑ "Valneva's Clostridium difficile vaccine candidate - VLA84". Retrieved 2017-04-25.
- ↑ "Valneva's Lyme disease vaccine candidate - VLA15". Retrieved 2017-04-25.
- ↑ "Valneva writes off hospital-acquired infection vaccine following PhII/III miss". FierceBiotech, Questex LLC. 2016-09-01. Retrieved 2017-04-25.
- ↑ "Merck ends trial of Intercell's MRSA vaccine". REUTERS. 2011-06-08. Retrieved 2017-04-25.
- ↑ "Intercell Hepatitis C Vaccine Meets Primary Endpoints". FDA News. 2007-08-22. Retrieved 2008-08-15.
External links
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.